Panbela Therapeutics Inc. [PBLA] is -79.48% lower this YTD. Is it still time to buy?


Panbela Therapeutics Inc. [NASDAQ: PBLA] The price rose 46.39 percent to $0.11. Company report on August 15, 2022 Panbela provides a business update and reports financial results for the second quarter of 2022.

Top 5 cheap stocks to own right now

While finding safe stocks with the potential for huge gains isn’t always easy, we’ve found a few that can pay off well. In fact, within our report, Top 5 cheap stocks to own right nowIn this article, we have identified five stocks that we believe can increase in value even if you have $1,000 to invest.

Register here to get a free report now. .

sponsored by

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage company that develops disruptive therapies to treat patients with urgent unmet medical needs, today provides a business update and financial results reports for the quarter ending June 30, 2022. Management is hosting an earnings conference call today at 4: 30 p.m. ET.

4121374 shares were traded in the last session while the average daily trading volume was 392.00 thousand shares. Shares of Panbela Therapeutics Inc reached a high of $0.4419 and fell to a low of $0.2028 to finish at $0.35 in the last session.

PBLA’s 1-year forecast is for a potential rise of 95.62. The average equity rating of PBLA stock is currently 2.00, and it is trading near a bullish pattern in the stock market.

Educator’s opinion of Panbela Therapeutics Inc. [PBLA]:

Based on careful and fact-backed analysis by Wall Street experts, the current consensus on a target price for PBLA shares is $8.00 per share. Target price analysis and stock performance are usually carefully studied by market experts, and the current Wall Street consensus for PBLA stock is a set recommendation at 2.00. This rating represents a strong buy recommendation, on a scale of 1 to 5, where 5 means strong sell, 4 represents sell, 3 represents hold, and 2 indicates buy.

PBLA stock performance analysis:

Panbela Therapeutics Inc. [PBLA] It fell into the red last weekend, fell in a negative direction and fell by -6.33. With this latest performance, PBLA shares are down -55.61% over the past four-week period, as well as down -82.68% over the past six months — not to mention a -84.43% drop in the last year of trading.

Overbought and oversold stocks can be easily tracked by the Relative Strength Index (RSI), where an RSI result of over 70 is overbought, and any price below 30 indicates oversold conditions. The RSI of 50 represents neutral momentum in the market. The current RSI for the PBLA stock for the past two weeks was set at 35.63, with the RSI for the last one trading at 38.18, and the three-week RSI set at 35.50 for Panbela Therapeutics Inc. [PBLA]. The current moving average for the last 50 trading days for this stock is 0.9139 while it recorded at 0.3520 for the last trading week, and 1.4998 for the last 200 days.

An insight into the fundamentals of Panbela Therapeutics Inc.

The return on equity for this stock fell to -108.63, with the return on assets remaining at -89.35.

The liquidity data of Panbela Therapeutics Inc. Interesting too, with the quick ratio at 0.60 and the current ratio at 0.60.

Panbela Therapeutics Inc. [PBLA] Insiders’ position details

There are currently approximately $0 million, or 0.80% of PBLA’s stock, in the hands of institutional investors. The three largest PBLA shareholders are: BRAND ASSET MANAGEMENT GROUP, INC. With 57,144 ownership, which is approximately 0% of the company’s market capitalization and approximately 1.60% of the total institutional ownership; BUCKINGHAM STRATEGIC WEALTH, LLC, owns 24,927 shares of stock with an approximate value of $9000.0 in PBLA stock; and SUSQUEHANNA INTERNATIONAL GROUP, LLP, currently worth $7000.0 in PBLA stock with ownership of nearly New of the company’s market value.

Positions increased in the shares of Panbela Therapeutics Inc. held by institutional investors at the end of August and at the time of the August report, as 5 institutional owners consolidated their position in Panbela Therapeutics Inc. [NASDAQ:PBLA] About 56,798 shares. In addition, the number of 7 investors decreased positions by about 730,714 shares, while 7 investors held positions by 616,085 shares. The said changes put institutional holdings at 171,427 shares, according to the latest report from the Securities and Exchange Commission. PBLA 3 stock had new institutional investments with a total of 45,333 shares, while 6 institutional investors sold deals totaling 729,722 shares during the same period.

Leave A Reply

Your email address will not be published.